Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is rising worldwide with the increasing incidence of obesity, Type 2 diabetes mellitus and metabolic syndrome. NASH is currently one of the most common indications of liver transplantation in the United States. The immune system plays a major role in the pathogenesis of NAFLD/NASH. The metabolic changes, associated with obesity and metabolic syndrome, induce immunological responses resulting in NAFLD and further aggravation of the metabolic derangement in a feed-forward loop. Genetic and endocrine factors modulate the immunological and metabolic responses and determine the pathophysiological features of NAFLD. Histologically, NAFLD is a spectrum that ranges from simple hepatic steatosis to severe steatohepatitis, liver cirrhosis and/or hepatocellular carcinoma. Liver cirrhosis and hepatocellular carcinoma are responsible for the morbidity and mortality of the disease. This article is a critical evaluation of our current knowledge of the immunological and molecular basis of the disease.
| Original language | English |
|---|---|
| Pages (from-to) | 727-738 |
| Number of pages | 12 |
| Journal | Expert Review of Clinical Immunology |
| Volume | 9 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Cite this
Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. / Radwan, Mohamed M.; Radwan, Basil M.; Nandipati, Kalyana C.; Hunter, William J.; Agrawal, Devendra K.
In: Expert Review of Clinical Immunology, Vol. 9, No. 8, 08.2013, p. 727-738.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
AU - Radwan, Mohamed M.
AU - Radwan, Basil M.
AU - Nandipati, Kalyana C.
AU - Hunter, William J.
AU - Agrawal, Devendra K.
PY - 2013/8
Y1 - 2013/8
N2 - The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is rising worldwide with the increasing incidence of obesity, Type 2 diabetes mellitus and metabolic syndrome. NASH is currently one of the most common indications of liver transplantation in the United States. The immune system plays a major role in the pathogenesis of NAFLD/NASH. The metabolic changes, associated with obesity and metabolic syndrome, induce immunological responses resulting in NAFLD and further aggravation of the metabolic derangement in a feed-forward loop. Genetic and endocrine factors modulate the immunological and metabolic responses and determine the pathophysiological features of NAFLD. Histologically, NAFLD is a spectrum that ranges from simple hepatic steatosis to severe steatohepatitis, liver cirrhosis and/or hepatocellular carcinoma. Liver cirrhosis and hepatocellular carcinoma are responsible for the morbidity and mortality of the disease. This article is a critical evaluation of our current knowledge of the immunological and molecular basis of the disease.
AB - The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is rising worldwide with the increasing incidence of obesity, Type 2 diabetes mellitus and metabolic syndrome. NASH is currently one of the most common indications of liver transplantation in the United States. The immune system plays a major role in the pathogenesis of NAFLD/NASH. The metabolic changes, associated with obesity and metabolic syndrome, induce immunological responses resulting in NAFLD and further aggravation of the metabolic derangement in a feed-forward loop. Genetic and endocrine factors modulate the immunological and metabolic responses and determine the pathophysiological features of NAFLD. Histologically, NAFLD is a spectrum that ranges from simple hepatic steatosis to severe steatohepatitis, liver cirrhosis and/or hepatocellular carcinoma. Liver cirrhosis and hepatocellular carcinoma are responsible for the morbidity and mortality of the disease. This article is a critical evaluation of our current knowledge of the immunological and molecular basis of the disease.
UR - http://www.scopus.com/inward/record.url?scp=84887854440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887854440&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2013.816484
DO - 10.1586/1744666X.2013.816484
M3 - Review article
VL - 9
SP - 727
EP - 738
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 8
ER -